908 Devices Inc. (MASS) vs Nuvectis Pharma, Inc. (NVCT)
A side-by-side comparison of 908 Devices Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MASS
908 Devices Inc.
$12.42HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
NVCT
Nuvectis Pharma, Inc.
$20.36HealthcareDelayed quote: Oct 6, 2026, 12:53 PM EDT
Total return — MASS vs NVCT
growth of $100 · dividends reinvested · last 5yMASS -16.0% (-3.4%/yr)NVCT +558.2% (+45.8%/yr)NVCT compounded faster over this window
Log scale — wide-divergence pair
MASS NVCT
MASS vs NVCT: by the numbers
- •NVCT is the larger company ($540M vs $510M market cap).
- •Both run net losses; NVCT's is the smaller (0.00% vs -56.68% net margin).
Metrics side by side
Valuation
| Metric | MASS | NVCT |
|---|---|---|
| P/S ratio | 8.38 | N/A |
| P/B ratio | 4.02 | 59.49 |
| FCF yield | 0.09% | N/A |
Profitability
| Metric | MASS | NVCT |
|---|---|---|
| Gross margin | 49.79% | 0.00% |
| Operating margin | -46.01% | 0.00% |
| Net margin | -56.68% | 0.00% |
| ROE | -27.20% | -306.61% |
| ROIC | -18.90% | -317.86% |
Growth (annualized)
| Metric | MASS | NVCT |
|---|---|---|
| Revenue CAGR (5Y) | 18.92% | N/A |
| Total return CAGR (5Y) | -17.66% | N/A |
Go deeper
Dig into the metrics
908 Devices ROENuvectis Pharma ROE908 Devices operating marginNuvectis Pharma operating margin908 Devices revenue growthNuvectis Pharma revenue growth908 Devices free cash flowNuvectis Pharma free cash flow
908 Devices & Nuvectis Pharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.